POSNOC—POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes

Goyal, A; Mann, GB; Fallowfield, L; Duley, L; Reed, M; Dodwell, D; Coleman, RE; Fakis, A; Newcombe, R; Jenkins, V; Whitham, D; Childs, M; Whynes, D; Keeley, V; Ellis, I; Fairbrother, P; Sadiq, S; Monson, K; Montgomery, A; Tan, W; Vale, L; Homer, T; Badger, H; Haines, RH; Lewis, M; Brittain, C

Women's Health Collection

Journal article

POSNOC—POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes

Abstract:: Sentinel lymph node biopsy (SLNB) has become the gold standard for axillary lymph node staging, providing valuable prognostic information while minimizing complications compared to axillary lymph node dissection. However, there are ongoing debates and controversies surrounding SLNB in specific cases. Studies have explored the use of SLNB in neoadjuvant chemotherapy, emphasizing the need for customized therapy decisions. Factors such as age, tumor characteristics, and treatment response influence the selection of SLNB or axillary lymph node dissection. Additionally, the presence of extranodal extension, micrometastases, and isolated tumor cells has been evaluated to determine the need for lymphadenectomy. The importance of accurate oncological staging by thorough pathological evaluation has been highlighted, particularly with regards to invasion depth and lympho-vascular invasion. The significance of biological tumor status, such as hormone receptor and HER2 status, in axillary management decisions has been emphasized. Moreover, discussions have emerged regarding SLNB in the context of local recurrence, with differing perspectives on its utility. Future extensive studies are needed to refine protocols and incorporate these concepts related to SLNB into breast cancer management guidelines

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Goyal, A., Mann, G. B., Fallowfield, L., Duley, L., Reed, M., Dodwell, D., Coleman, R. E., Fakis, A., Newcombe, R., Jenkins, V., Whitham, D., Childs, M., Whynes, D., Keeley, V., Ellis, I., Fairbrother, P., Sadiq, S., Monson, K., Montgomery, A., … Brittain, C. (2021). POSNOC—POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open, 11(12), e054365–e054365.

MLA Style

Goyal, A, et al. “POSNOC—POsitive Sentinel NOde: Adjuvant Therapy Alone versus Adjuvant Therapy plus Clearance or Axillary Radiotherapy: a Randomised Controlled Trial of Axillary Treatment in Women with Early-Stage Breast Cancer Who Have Metastases in One or Two Sentinel Nodes.” BMJ Open, vol. 11, no. 12, 2021, pp. e054365–e054365.

Chicago Style

Goyal, A, GB Mann, L Fallowfield, et al. 2021. “POSNOC—POsitive Sentinel NOde: Adjuvant Therapy Alone versus Adjuvant Therapy plus Clearance or Axillary Radiotherapy: a Randomised Controlled Trial of Axillary Treatment in Women with Early-Stage Breast Cancer Who Have Metastases in One or Two Sentinel Nodes.” BMJ Open 11 (12): e054365–e054365.
Print